# US 2012/0251620 A1 · Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251620 A1
- Document ID: US20120251620A1
- Status: Published application
- Kind: A1
- Application number: 13/506,783
- Filed: 2012-05-16
- Published: 2012-10-04
- Earliest claimed: 2003-03-05
- Assignees: Halozyme, Inc.
- Inventors: Louis H. Bookbinder; Anirban Kundu; Gregory I. Frost
- Web page: https://patentgrep.com/patent/US20120251620A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/04: Amoebicides
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/2474: {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
- C12Y 302/01035: Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

## Claims

### Claim 1

A method for treating a subject having edema, comprising administering a hyaluronidase glycoprotein to treat the edema, wherein the hyaluronidase glycoprotein:
contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide;
is neutral active; and
consists of either:
a) a sequence of amino acids contained within SEQ ID NO:1 that includes amino acids 36-464 of SEQ ID NO: 1 and is truncated within the C-terminal region of SEQ ID NO:1 so that it does not comprise the full-length of the polypeptide whose sequence is set forth in SEQ ID NO:1; or
b) contains amino acid substitutions in the sequence of amino acids of a), whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least about 95% amino acid sequence identity with the sequence of amino acids

### Claim 2 (depends on 1)

The method of claim 1, wherein the edema is interstitial edema, edema associated with retention of water and wastes associated with fat overloading of lipocytes, edema following head trauma or edema associated with brain tumors.

### Claim 3 (depends on 1)

The method of claim 1, wherein the hyaluronidase glycoprotein is administered systemically.

### Claim 4 (depends on 1)

The method of claim 1, wherein the glycoprotein is administered locally.

### Claim 5 (depends on 4)

The method of claim 4, wherein the glycoprotein is administered locally in a slow release delivery vehicle.

### Claim 6 (depends on 5)

The method of claim 5, wherein the slow release delivery vehicle is a colloidal dispersion system or polymer stabilized crystals.

### Claim 7 (depends on 6)

The method of claim 6, wherein the vehicle is a colloidal dispersion system selected from among nanocapsules, microspheres, beads, lipid-based systems and oil-in-water emulsions.

### Claim 8 (depends on 7)

The method of claim 7, wherein the vehicle is an oil-in-water emulsion selected from among micelles, mixed micelles and liposomes.

### Claim 9 (depends on 5)

The method of claim 5, wherein the slow release delivery vehicle is selected from among biodegradable hydrogel matrices, dendritic polymer conjugates and multivesicular liposomes.

### Claim 10 (depends on 1)

The method of claim 1, wherein the glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, or contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least about 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 98% amino acid sequence identity to a sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO:1.

### Claim 12 (depends on 1)

The method of claim 1, wherein the glycoprotein consists of a sequence of amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1.

### Claim 13 (depends on 1)

The method of claim 1, wherein the glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least about 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

### Claim 14 (depends on 1)

The method of claim 1, wherein the glycoprotein is modified with a polymer.

### Claim 15 (depends on 13)

The method of claim 13, wherein the polymer is a polyethylene glycol (PEG) or a dextran.

### Claim 16 (depends on 3)

The method of claim 3, wherein the glycoprotein is modified with a polymer.

### Claim 17 (depends on 15)

The method of claim 15, wherein the polymer is a polyethylene glycol (PEG) or a dextran.

### Claim 18 (depends on 1)

The method of claim 1, wherein the glycoprotein is produced in and secreted from a mammalian cell by a method comprising:
introducing an expression vector comprising a polynucleotide that consists of a sequence of nucleotides set forth as nucleotides 106-1446 of SEQ ID NO:6 or degenerates thereof or the sequence of nucleotides set forth in SEQ ID NO:48 or degenerates thereof inserted between flanking sequences in the vector into a mammalian cell;
culturing the mammalian cell under conditions whereby the glycoprotein is expressed and secreted by the cell; and
recovering a composition comprising the expressed and secreted hyaluronidase glycoprotein.

### Claim 19 (depends on 1)

The method of claim 1, wherein a composition comprising the hyaluronidase glycoprotein that consists of the sequence of amino acids set forth as amino acids 36-482 of SEQ ID NO:1 is administered.

### Claim 20 (depends on 1)

The method of claim 1, wherein the glycoprotein:
a) consists of a C-terminally truncated polypeptide of SEQ ID NO:1 that includes at least amino acids 36-464 of SEQ ID NO:1, wherein the truncation is at a residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1; or
b) contains amino acid substitutions in the polypeptide of a), whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence that has at least about 95% amino acid sequence identity with the polypeptide of a); or
c) has more than 99% sequence identity with the polypeptide of a); or
d) has more than 97% sequence identity with the polypeptide of a), wherein truncation is at residue 483.
